Regulus Therapeutics Inc (RGLS)

NASDAQ
Currency in USD
7.8800
-0.3300(-4.02%)
Closed·
After Hours
7.9700+0.0800(+1.0139%)
·
RGLS Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Unusual trading volume
Fair Value
Day's Range
7.75008.2399
52 wk Range
0.83018.3450
Key Statistics
Edit
Prev. Close
8.21
Open
8.2
Day's Range
7.75-8.2399
52 wk Range
0.8301-8.345
Volume
17.02M
Average Volume (3m)
2.31M
1-Year Change
212.7%
Book Value / Share
1.04
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
RGLS Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
8.8000
Upside
+11.68%
Members' Sentiments
Bearish
Bullish
ProTips
2 analysts have revised their earnings upwards for the upcoming period

Regulus Therapeutics Inc News & Analysis

Show more

Regulus Therapeutics Inc Company Profile

Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. The company develops farabursen, an anti-miR oligonucleotide targeting miR-17 in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. It is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. The company has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. and Ionis Pharmaceuticals, Inc. to develop, manufacture, and commercialize products covered by the licensed patent rights for use in microRNA compounds. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Compare RGLS to Peers and Sector

Metrics to compare
RGLS
Peers
Sector
Relationship
P/E Ratio
−12.5x−4.7x−0.5x
PEG Ratio
−0.250.100.00
Price/Book
8.6x2.5x2.6x
Price / LTM Sales
-2,961.6x3.0x
Upside (Analyst Target)
14.2%230.1%52.6%
Fair Value Upside
Unlock15.0%8.8%Unlock

Analyst Ratings

2 Buy
4 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 8.8000
(+11.68% Upside)

Earnings

Latest Release
May 08, 2025
EPS / Forecast
-0.15 / -0.25
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

RGLS Income Statement

FAQ

What Is the Regulus Therapeutics (RGLS) Stock Price Today?

The Regulus Therapeutics stock price today is 7.88

What Stock Exchange Does Regulus Therapeutics Trade On?

Regulus Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Regulus Therapeutics?

The stock symbol for Regulus Therapeutics is "RGLS."

What Is the Regulus Therapeutics Market Cap?

As of today, Regulus Therapeutics market cap is 595.82M.

What Is Regulus Therapeutics's Earnings Per Share (TTM)?

The Regulus Therapeutics EPS (TTM) is -0.72.

When Is the Next Regulus Therapeutics Earnings Date?

Regulus Therapeutics will release its next earnings report on 11 Aug 2025.

From a Technical Analysis Perspective, Is RGLS a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.

How Many Times Has Regulus Therapeutics Stock Split?

Regulus Therapeutics has split 3 times.

How Many Employees Does Regulus Therapeutics Have?

Regulus Therapeutics has 34 employees.

What is the current trading status of Regulus Therapeutics (RGLS)?

As of 21 Jun 2025, Regulus Therapeutics (RGLS) is trading at a price of 7.88, with a previous close of 8.21. The stock has fluctuated within a day range of 7.75 to 8.24, while its 52-week range spans from 0.83 to 8.35.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.